China To Produce Generic Anti-Hepatitis B Virus Drug Entecavir
This article was originally published in PharmAsia News
Executive Summary
Hainan Zhonghe Pharmaceutical has obtained clinical trial approval for entecavir tablets, marking China's capability to produce a first-line drug for chronic hepatitis B treatment. Locally made entecavir, expected to be marketed in 2010, will provide patients with a lower-priced option. Baraclude, the imported entecavir marketed in the country by Sino-American Shanghai Squibb Pharmaceuticals since 2006, has been enjoying brisk sales. However, the new generic entecavir will likely impact Baraclude sales and possibly even restructure the domestic anti-hepatitis B drug market. (Click here for more - Chinese Language)